Inadequate Evidence for Albumin in Severe Malaria
Author Information
Author(s): Charles J. Woodrow, Timothy Planche
Primary Institution: St. George's University of London
Hypothesis
Can albumin reduce mortality in severe malaria by over 80%?
Conclusion
The study found no significant difference in outcomes between albumin and Gelofusine in treating severe malaria.
Supporting Evidence
- The study found no significant difference between albumin and Gelofusine in any outcome measure.
- The authors propose further studies of albumin despite the lack of evidence.
- Allocation concealment was not incorporated in the study design.
Takeaway
The study looked at two treatments for severe malaria and found they worked about the same, so we need to be careful about which one we use.
Methodology
The study compared the effects of albumin and Gelofusine on children with severe malaria.
Potential Biases
There were concerns about the inclusion of patients who did not meet criteria and how that may have influenced results.
Limitations
The study design lacked allocation concealment and had potential biases in patient inclusion.
Participant Demographics
Children with severe malaria.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website